BioSpace News Archive

The data showed mixed end results, but the diagnostics involved in treating Alzheimer’s were the star of the conference.

With the International Conference on Alzheimer’s and Parkinson’s Diseases still ongoing, there has been increased news about Alzheimer’s. Here’s a look at just a few of the latest stories.

Martin Shkreli will not be able to delay paying nearly $25 million he owes from a civil lawsuit that he and his company employed on Daraprim.

It was a busy week for clinical trial announcements. Here’s a look.

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced final results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa for the potential treatment of Fabry disease.

ASLAN Pharmaceuticals today announced that an abstract highlighting key efficacy and safety data from the completed Phase 1b study for eblasakimab (ASLAN004) in atopic dermatitis (AD) has been accepted for late-breaking oral presentation at the 2022 American Academy of Dermatology Annual Meeting, to be held in-person March 25-29, 2022, in Boston, Massachusetts.

DENTSPLY SIRONA Inc. announced that the Company will participate in the Piper Sandler Virtual Dental Day.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data from its Phase IIb AIPAC trial at ESMO’s Breast Cancer Congress 2022, which will take place onsite in Berlin, Germany and virtually on 3-5 May 2022.

Biocept, Inc. (Nasdaq: BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange Commission (SEC) on Thursday, March 31, 2022.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 3,030,304 common shares at a purchase price of $1.65 per share.